<DOC>
	<DOCNO>NCT00421811</DOCNO>
	<brief_summary>N-cadherin , protein involved blood vessel cell bind surface many tumor cell , increase cancer progress . ADH-1 block N-cadherin . This study test safety effect combination ADH-1 Normothermic Isolated Limb Infusion Melphalan subject locally advanced malignant melanoma .</brief_summary>
	<brief_title>A Study ADH-1 Combination With Normothermic Isolated Limb Infusion Melphalan</brief_title>
	<detailed_description />
	<mesh_term>Melphalan</mesh_term>
	<criteria>Signed write informed consent Male female patient &gt; = 18 year age diagnosis melanoma treatment Normothermic Isolated Limb Infusion ( ILI ) melphalan would appropriate Measurable disease Disease site ( ) must distal planned site tourniquet placement Available immunohistochemical test Ncadherin expression tumor tissue Adequate performance status organ function , evidence hematological biochemical blood test ECG Receipt ADH1 prior clinical study ( prior melphalan via ILI , okay ) Stage IV melanoma Chemotherapy , radiotherapy , investigational drug within 4 week study entry History tumor show clinically significant evidence active bleeding within 12 week study entry Stroke , major surgery , major tissue injury within 4 week study entry Uncontrolled congestive heart failure , coronary artery disease , life threaten arrhythmia ; myocardial infarction within 12 month ; significant electrocardiogram ( ECG ) abnormalities Allergic reaction therapeutic peptide melphalan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>melanoma</keyword>
	<keyword>anticarcinogenic agent</keyword>
	<keyword>antineoplastic agent</keyword>
	<keyword>cadherins</keyword>
	<keyword>solid tumor</keyword>
</DOC>